ASH 2018 | PHOENIX: ibrutinib in combination with R-CHOP for DLBCL

Stephen Ansell

Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MI, introduces the Phase III PHOENIX trial (NCT01855750) evaluating whether ibrutinib in combination with R-CHOP improves the clinical outcome of patients with newly diagnosed non-GBC diffuse large B-cell lymphoma. Prof. Ansell speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, revealing the unmet primary endpoint of event-free survival, before discussing the significant benefit of the addition of ibrutinib for the younger and fitter patients.

Share this video